Co-founded by Innovative Targeting Solutions, A2 Biotherapeutics has emerged from stealth with $57m in series A financing to develop cell therapies for cancer.
A2 Biotherapeutics, a US-based cancer-focused biotechnology developer co-founded by biotech firm Innovative Targeting Solutions, yesterday emerged from stealth with a $57m series A round.
The series A round was backed by Column Group, Vida Ventures, Samsara BioCapital and Nextech Invest.
Founded in 2018, A2 Biotherapeutics is working on technology that identifies antibody and T-cell receptor fragments that can distinguish healthy cells from tumour cells, thereby avoiding the former being unintentionally killed by cancer therapies.
Traditional approaches are based on tumour-specific…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
